Pursuing Pharmacoequity : Determinants, Drivers, and Pathways to Progress
Copyright © 2022 by Duke University Press..
The United States pays more for medical care than any other nation in the world, including for prescription drugs. These costs are inequitably distributed, as individuals from underrepresented racial and ethnic groups in the United States experience the highest costs of care and unequal access to high-quality, evidence-based medication therapy. Pharmacoequity refers to equity in access to pharmacotherapies or ensuring that all patients, regardless of race and ethnicity, socioeconomic status, or availability of resources, have access to the highest quality of pharmacotherapy required to manage their health conditions. Herein the authors describe the urgent need to prioritize pharmacoequity. This goal will require a bold and innovative examination of social policy, research infrastructure, patient and prescriber characteristics, as well as health policy determinants of inequitable medication access. In this article, the authors describe these determinants, identify drivers of ongoing inequities in prescription drug access, and provide a framework for the path toward achieving pharmacoequity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Journal of health politics, policy and law - 47(2022), 6 vom: 01. Dez., Seite 709-729 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chalasani, Rohan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Health policy |
|---|
| Anmerkungen: |
Date Completed 26.12.2022 Date Revised 30.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1215/03616878-10041135 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343874709 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343874709 | ||
| 003 | DE-627 | ||
| 005 | 20231226021448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1215/03616878-10041135 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1146.xml |
| 035 | |a (DE-627)NLM343874709 | ||
| 035 | |a (NLM)35867522 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chalasani, Rohan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pursuing Pharmacoequity |b Determinants, Drivers, and Pathways to Progress |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.12.2022 | ||
| 500 | |a Date Revised 30.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 by Duke University Press. | ||
| 520 | |a The United States pays more for medical care than any other nation in the world, including for prescription drugs. These costs are inequitably distributed, as individuals from underrepresented racial and ethnic groups in the United States experience the highest costs of care and unequal access to high-quality, evidence-based medication therapy. Pharmacoequity refers to equity in access to pharmacotherapies or ensuring that all patients, regardless of race and ethnicity, socioeconomic status, or availability of resources, have access to the highest quality of pharmacotherapy required to manage their health conditions. Herein the authors describe the urgent need to prioritize pharmacoequity. This goal will require a bold and innovative examination of social policy, research infrastructure, patient and prescriber characteristics, as well as health policy determinants of inequitable medication access. In this article, the authors describe these determinants, identify drivers of ongoing inequities in prescription drug access, and provide a framework for the path toward achieving pharmacoequity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a health policy | |
| 650 | 4 | |a pharmacoequity | |
| 650 | 4 | |a race and ethnicity | |
| 650 | 4 | |a racism | |
| 650 | 4 | |a social determinants | |
| 700 | 1 | |a Krishnamurthy, Sudarshan |e verfasserin |4 aut | |
| 700 | 1 | |a Suda, Katie J |e verfasserin |4 aut | |
| 700 | 1 | |a Newman, Terri V |e verfasserin |4 aut | |
| 700 | 1 | |a Delaney, Scott W |e verfasserin |4 aut | |
| 700 | 1 | |a Essien, Utibe R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of health politics, policy and law |d 1980 |g 47(2022), 6 vom: 01. Dez., Seite 709-729 |w (DE-627)NLM000221155 |x 1527-1927 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2022 |g number:6 |g day:01 |g month:12 |g pages:709-729 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1215/03616878-10041135 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2022 |e 6 |b 01 |c 12 |h 709-729 | ||